Targeting mTOR pathway: A new concept in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Cell Biology

Background:

• The mechanistic target of rapamycin (mTOR) pathway is crucial for coordinating cellular responses to growth signals and nutrient availability.
• Deregulation of mTOR signaling is implicated in the pathogenesis and progression of numerous cancer types.
• mTOR influences cell cycle progression, nutrient uptake, and angiogenesis, all vital processes in tumor development.

Purpose of the Study:

• To review current knowledge of mTOR biology and its specific roles in various cancers.
• To explore the therapeutic potential of mTOR inhibitors in oncology.
• To highlight the clinical significance of Everolimus in advanced renal cell carcinoma.

Main Methods:

• Literature review of mTOR biology and its involvement in cancer.
• Analysis of mTOR's regulatory mechanisms on cell cycle, nutrient transport, and angiogenesis.
• Examination of clinical trial data for mTOR inhibitors, particularly Everolimus.

Main Results:

• mTOR controls cell proliferation via cyclin D1 and nutrient transporters, supporting abnormal cell growth.
• mTOR promotes angiogenesis by increasing hypoxia-inducible factors (HIFs) and growth factors like VEGF.
• Emerging evidence links mTOR activation to enhanced cancer cell survival through antiapoptotic proteins.
• Everolimus is the first mTOR inhibitor with Phase III evidence for advanced renal cell carcinoma after VEGF-targeted therapy failure.

Conclusions:

• The mTOR pathway is a critical regulator of cancer cell growth, survival, and angiogenesis.
• Targeting the mTOR pathway with inhibitors represents a promising therapeutic strategy for diverse cancer types.
• Everolimus provides a new treatment option for patients with advanced renal cell carcinoma progressing after VEGF-targeted therapy.